ADVERTISEMENT
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies

Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.

Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.

disease & medicine, biobusiness, drug development

computing a cure
Artificial Intelligence Shakes Up Drug Discovery
Bianca Nogrady | May 1, 2019 | 8 min read
The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.
small-molecule therapeutics treat cancer and other diseases
Scientists Take Aim at Disease-Causing RNAs Using Small-Molecule Drugs
Claire Asher | Apr 1, 2019 | 9 min read
Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions.
New Treatments for Phenylketonuria Aim to Loosen Reins on Strict Diet
Diana Kwon | May 29, 2018 | 5 min read
Biotechs have developed enzyme replacements and genetically modified probiotics to treat patients with the rare metabolic disorder.
ADVERTISEMENT